PRODUCT DETAILS
- RLD: CARDIZEM LA®
- Strength: Available in 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, and 420 mg Tablets
- Therapeutic Class: Cardiovascular Agent
PRODUCT DETAILS
| Strength | NDC Number | Saleable Unit | Wholesaler Numbers |
|---|---|---|---|
| 120 mg | 70436-195-04 | Bottle of 30 | Cardinal Health: 5832423 |
| McKesson: 2689669 | |||
| Amerisource: 10278142 | |||
| 180 mg | 70436-196-04 | Bottle of 30 | Cardinal Health: 5832449 |
| McKesson: 2689677 | |||
| Amerisource: 10278147 | |||
| 240 mg | 70436-197-04 | Bottle of 30 | Cardinal Health: 5832464 |
| McKesson: 2689685 | |||
| Amerisource: 10278149 | |||
| 300 mg | 70436-198-04 | Bottle of 30 | Cardinal Health: 5832480 |
| McKesson: 2689693 | |||
| Amerisource: 10278170 | |||
| 360 mg | 70436-199-04 | Bottle of 30 | Cardinal Health: 5832340 |
| McKesson: 2689701 | |||
| Amerisource: 10278160 | |||
| 420 mg | 70436-200-04 | Bottle of 30 | Cardinal Health: 5832365 |
| McKesson: 2689651 | |||
| Amerisource: 10278084 |
Diltiazem Hydrochloride Extended-Release Tablets are supplied as follows:
120 mg, white to off-white capsules-shaped tablet, debossed with “
” on one side and “157” on the other side.
180 mg, white to off-white capsules-shaped tablet, debossed with “” on one side and “156” on the other side.
240 mg, white to off-white capsules-shaped tablet, debossed with “” on one side and “155” on the other side.
300 mg, white to off-white capsules-shaped tablet, debossed with “” on one side and “153” on the other side.
360 mg, white to off-white capsules-shaped tablet, debossed with “” on one side and “152” on the other side.
420 mg, white to off-white capsules-shaped tablet, debossed with “” on one side and “15” on the other side.
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
Avoid excessive humidity and temperatures above 30°C (86°F).
We have been made aware of recent scams that offer false employment opportunities or request financial commitments purportedly on behalf of Slate Run Pharmaceuticals. Unsuspecting job seekers have reported receiving unsolicited contacts such as e-mails and phone calls which may request personal information or offers of employment. Please note that these communications are fraudulent and are not affiliated with Slate Run Pharmaceuticals. Slate Run Pharmaceuticals never requires a financial deposit for employment consideration nor do we offer unsolicited employment packages.
You can reach out to Slate Run Pharmaceuticals at http://www.slaterunpharma.com/get-in-touch/. If you receive a suspicious proposal, please contact your local law enforcement agency for guidance.